Arvinas, Inc.
ARVN$469M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNEW HAVEN430 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
7wMarket Overview
Stock performance and key metrics
ARVN News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Anastrozole
Breast Cancer
ARV-471
Breast Cancer
ARV-110
Prostate Cancer Metastatic
ARV-806
KRAS G12D Mutation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Anastrozole | Phase 2 | Breast Cancer | - | |
ARV-471 | Phase 2 | Breast Cancer | - | - |
ARV-110 | Phase 2 | Prostate Cancer Metastatic | - | - |
ARV-806 | Phase 2 | KRAS G12D Mutation | - | - |
Breast Cancer
2 drugs in this indication
KRAS G12D Mutation
1 drug in this indication
Prostate Cancer Metastatic
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply